European Initiative Hepatitis C and Drug Use

The burden of HCV is concentrated among people who inject drugs (PWID) in Europe, with HCV antibody prevalence ranging from 20% to over 90% in different countries.

The burden of HCV is concentrated among people who inject drugs (PWID) in Europe, with HCV antibody prevalence ranging from 20% to over 90% in different countries.

Related Resources